Respiratorius Past Earnings Performance
Past criteria checks 0/6
Respiratorius's earnings have been declining at an average annual rate of -18.5%, while the Biotechs industry saw earnings growing at 17.7% annually.
Key information
-18.5%
Earnings growth rate
-0.2%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | n/a |
| Return on equity | -29.5% |
| Net Margin | n/a |
| Next Earnings Update | 21 May 2024 |
Revenue & Expenses Breakdown
How Respiratorius makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -8 | 5 | -1 |
| 31 Dec 22 | 0 | -13 | 11 | -1 |
| 30 Apr 22 | 0 | -13 | 10 | -2 |
| 31 Dec 21 | 0 | -10 | 8 | -18 |
| 30 Sep 21 | 0 | -9 | 8 | -6 |
| 30 Jun 21 | 0 | -8 | 7 | -6 |
| 31 Mar 21 | 0 | -8 | 6 | -5 |
| 31 Dec 20 | 0 | -7 | 5 | -5 |
| 30 Sep 20 | 0 | -6 | 4 | -5 |
| 30 Jun 20 | 0 | -6 | 3 | -4 |
| 31 Mar 20 | 0 | -5 | 4 | -6 |
| 31 Dec 19 | 0 | -5 | 4 | -6 |
| 30 Sep 19 | 0 | -5 | 6 | -4 |
| 30 Jun 19 | 0 | -5 | 6 | -4 |
| 31 Mar 19 | 0 | -6 | 5 | -3 |
| 31 Dec 18 | 0 | -5 | 4 | -2 |
| 30 Sep 18 | 0 | -5 | 4 | -2 |
| 30 Jun 18 | 0 | -5 | 4 | -2 |
| 31 Mar 18 | 0 | -5 | 4 | -2 |
| 31 Dec 17 | 0 | -5 | 4 | -2 |
| 30 Sep 17 | 0 | -5 | 3 | 0 |
| 30 Jun 17 | 0 | -5 | 4 | -2 |
| 31 Mar 17 | 0 | -5 | 3 | -1 |
| 31 Dec 16 | 0 | -5 | 3 | -2 |
| 30 Sep 16 | 0 | -5 | 4 | -4 |
| 30 Jun 16 | 0 | -5 | 3 | -2 |
| 31 Mar 16 | 0 | -5 | 3 | -2 |
| 31 Dec 15 | 0 | -6 | 3 | -2 |
| 30 Sep 15 | 0 | -6 | 3 | -2 |
| 30 Jun 15 | 0 | -6 | 3 | -2 |
| 31 Mar 15 | 0 | -6 | 3 | -2 |
| 31 Dec 14 | 0 | -5 | 3 | -2 |
| 30 Sep 14 | 0 | -5 | 3 | -1 |
| 30 Jun 14 | 0 | -5 | 2 | -1 |
| 31 Mar 14 | 0 | -5 | 2 | -1 |
| 31 Dec 13 | 0 | -5 | 2 | -1 |
| 30 Sep 13 | 0 | -5 | 3 | -2 |
Quality Earnings: RESP is currently unprofitable.
Growing Profit Margin: RESP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: RESP is unprofitable, and losses have increased over the past 5 years at a rate of 18.5% per year.
Accelerating Growth: Unable to compare RESP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RESP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: RESP has a negative Return on Equity (-29.54%), as it is currently unprofitable.